A detailed history of Sg Americas Securities, LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 22,917 shares of REPL stock, worth $286,462. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,917
Holding current value
$286,462
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$8.09 - $11.23 $185,398 - $257,357
22,917 New
22,917 $251,000
Q1 2024

May 06, 2024

BUY
$6.87 - $9.31 $123,440 - $167,282
17,968 New
17,968 $147,000
Q1 2023

Apr 28, 2023

SELL
$17.48 - $29.09 $29,908 - $49,772
-1,711 Reduced 12.48%
12,003 $212,000
Q4 2022

Feb 02, 2023

SELL
$17.09 - $27.91 $83,809 - $136,870
-4,904 Reduced 26.34%
13,714 $373,000
Q3 2022

Oct 31, 2022

SELL
$15.6 - $21.15 $210,303 - $285,123
-13,481 Reduced 42.0%
18,618 $322,000
Q2 2022

Jul 29, 2022

SELL
$13.32 - $19.98 $790,941 - $1.19 Million
-59,380 Reduced 64.91%
32,099 $561,000
Q1 2022

Apr 29, 2022

BUY
$15.24 - $29.75 $353,552 - $690,170
23,199 Added 33.98%
91,479 $1.55 Million
Q4 2021

Feb 07, 2022

BUY
$25.43 - $34.25 $1.32 Million - $1.78 Million
52,019 Added 319.9%
68,280 $1.85 Million
Q3 2021

Nov 01, 2021

BUY
$28.98 - $39.54 $393,287 - $536,597
13,571 Added 504.5%
16,261 $482,000
Q2 2021

Aug 12, 2021

SELL
$28.5 - $39.37 $97,812 - $135,117
-3,432 Reduced 56.06%
2,690 $103,000
Q1 2021

May 13, 2021

BUY
$30.22 - $45.57 $44,816 - $67,580
1,483 Added 31.97%
6,122 $187,000
Q4 2020

Feb 04, 2021

BUY
$23.5 - $52.65 $109,016 - $244,243
4,639 New
4,639 $177,000
Q3 2020

Nov 09, 2020

SELL
$18.85 - $27.0 $176,624 - $252,990
-9,370 Closed
0 $0
Q2 2020

Jul 20, 2020

BUY
$9.76 - $25.95 $91,451 - $243,151
9,370 New
9,370 $233,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.